|
AU2007200203A1
|
|
Treatment of obesity
|
|
WO2007068039A1
|
|
Treatment of weight gain in estrogen deficient mammals
|
|
WO2007033427A1
|
|
Stabilisation of peptides with basic amino acids
|
|
AU2006275314A1
|
|
Peptide conjugate for oral delivery of hydrophilic peptide analgesics
|
|
US2011092448A1
|
|
Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
|
|
WO2006116808A1
|
|
Treating peripheral neuropathies
|
|
WO2006133477A1
|
|
Peptides corresponding to human growth hormone
|
|
CA2564169A1
|
|
Methods for preventing or treating bone disorders
|
|
CA2484396A1
|
|
Method for control of depression using c terminal growth hormone (gh) fragment
|
|
AU2003223252A1
|
|
Method for control of depression using c terminal growth hormone (gh) fragment
|
|
AU2003900899A0
|
|
Method for control of depression
|
|
AUPS210102A0
|
|
Method for control of depression
|
|
US2002142965A1
|
|
Treatment of obesity
|
|
AU8557501A
|
|
Product and method for control of obesity
|
|
WO0218436A1
|
|
Product and method for control of obesity
|
|
AU2001243942B2
|
|
Insulin potentiating peptides
|
|
WO0172770A1
|
|
Insulin potentiating peptides
|
|
AU1256001A
|
|
Product and method for control of obesity
|
|
AUPQ387599A0
|
|
Product and method for control of obesity
|
|
AUPQ019999A0
|
|
Insulin-potentiating compounds
|
